• Home
  • Search
  • Project Orbis: Global Collaborative Review Program.
  • Cite Icon61
  • https://doi.org/10.1158/1078-0432.ccr-20-3292Copy DOI Icon

Project Orbis: Global Collaborative Review Program.

Show More
  • Abstract
  • Literature Map
  • References
  • Citations
  • Similar Papers
Abstract

In 2019, the FDA Oncology Center of Excellence launched Project Orbis, a global collaborative review program to facilitate faster patient access to innovative cancer therapies across multiple countries. Project Orbis aims for concurrent submission, review, and regulatory action for high-impact clinically significant marketing applications among the participating partner countries. Current Project Orbis partners (POP) include the regulatory health authorities (RHA) of Australia, Brazil, Canada, Singapore, and Switzerland. Project Orbis leverages the existing scientific and regulatory partnerships between the various RHA under mutual confidentiality agreements. While FDA serves as the primary coordinator for application selection and review, each country remains fully independent on their final regulatory decision. In the first year of Project Orbis (June 2019 to June 2020), a total of 60 oncology marketing applications were received, representing 16 unique projects, and resulting in 38 approvals. New molecular entities, also known as new active substances, comprised 28% of the received marketing applications. The median time gap between FDA and Orbis submission dates was 0.6 months with a range of -0.8 to 9.0 months. Across the program, the median time-to-approval was similar between FDA (4.2 months, range 0.9-6.9, N = 18) and the POP (4.4 months, range 1.7-6.8, N = 20). Participating countries have signified a strong commitment for continuation and growth of the program. Project Orbis expansion considerations include the addition of more countries and management of more complex applications.

Similar Papers
  • Research Article
  • Citations25

Active pharmaceutical ingredients for antiretroviral treatment in low- and middle-income countries: a survey.

  • Apr 01, 2013
  • Antiviral Therapy
  • Joseph M Fortunak +5
  • Research Article
  • Citations1

Learning the intermolecular history of an API through the application of Hirshfeld surface analysis tools

  • Aug 23, 2022
  • Acta Crystallographica Section A Foundations and Advances
  • V Psycharis
  • PDF
  • Research Article
  • Citations22

Characterizations and Assays of α-Glucosidase Inhibition Activity on Gallic Acid Cocrystals: Can the Cocrystals be Defined as a New Chemical Entity During Binding with the α-Glucosidase?

  • Mar 05, 2020
  • Molecules
  • Na Xue +5
  • Book Chapter

New chemical entity (NCE)

  • Jan 01, 2009
  • Gerhard Nahler
  • Supplementary Content

Early ADMET profiling of anti-inflammatory alkaloids using validated LC-MS/MS methods

  • Jan 01, 2016
  • edoc (University of Basel)
  • Evelyn A Jähne
  • Research Article
  • Citations6

Reinvigorating cosmetic dermatology with the nanoparticle revolution

  • Dec 01, 2011
  • Journal of Cosmetic Dermatology
  • Zoe Diana Draelos
  • Research Article
  • Citations21

The FDA's Regulatory Framework for Chimeric Antigen Receptor-TCell Therapies.

  • Jul 22, 2019
  • Clinical and Translational Science
  • Peter Marks
  • Research Article
  • Citations8

Body of evidence and approaches applied in the clinical development programme of fixed-dose combinations in the European Union from 2010 to 2016.

  • Jun 17, 2019
  • British Journal of Clinical Pharmacology
  • Asbjørn Nøhr‐Nielsen +6
  • Research Article
  • Citations4

Surface-coated silica microparticles: In vitro and ex vivo evaluation of a preclinical extended release platform conceived for intravitreal injection.

  • May 01, 2025
  • Journal of controlled release : official journal of the Controlled Release Society
  • Marco Block +11
  • PDF
  • Research Article

Radiolabeled APIs for the Conduct of Human ADME Studies of Oncology Compounds

  • Dec 31, 2017
  • International Journal of Cancer and Clinical Research
  • Yuexian Li +2
  • Research Article
  • Citations31

A holistic review on zein nanoparticles and their use in phytochemicals delivery

  • May 27, 2022
  • Journal of Drug Delivery Science and Technology
  • Essraa A Hassan +3
  • Research Article
  • Citations8

Rampant online marketing of teeth whitening products: Evaluation of online information, labelling accuracy and quantitative analysis of high peroxide content gels

  • Aug 28, 2023
  • Heliyon
  • Márton Fittler +2
  • Research Article
  • Citations18

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review.

  • May 22, 2020
  • Targeted Oncology
  • Aye Myat Thi +3
  • Research Article
  • Citations272

Current Evaluation of the Millennium Phytomedicine- Ginseng (I): Etymology, Pharmacognosy, Phytochemistry, Market and Regulations

  • Jul 01, 2009
  • Current Medicinal Chemistry
  • Lee Jia +1
  • Research Article
  • Citations3

Case Study 6: Deconvoluting Hyperbilirubinemia-Differentiating Between Hepatotoxicity and Reversible Inhibition of UGT1A1, MRP2, or OATP1B1 in Drug Development.

  • Jan 01, 2021
  • Methods in molecular biology (Clifton, N.J.)
  • Ian Templeton +3
Cactus Communications logo

Copyright 2026 Cactus Communications. All rights reserved.